AbbVie (ABBV)
(Delayed Data from NYSE)
$215.89 USD
+3.93 (1.85%)
Updated Nov 4, 2025 04:04 PM ET
After-Market: $216.44 +0.55 (0.25%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABBV 215.89 +3.93(1.85%)
Will ABBV be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ABBV
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Pfizer (PFE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth
AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
Other News for ABBV
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
ABBV forms MACD Bearish Centerline Cross on November 3
AbbVie downgraded to Hold from Buy at DZ Bank
DZ Bank gets more bearish on AbbVie, downgrades shares
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Merus (MRUS)